This brand name is authorized in Estonia, Lithuania.
The drug TEIZEILD contains one active pharmaceutical ingredient (API):
1
|
UNII
S4M959U2IJ - TEPLIZUMAB
|
|
Teplizumab binds to CD3 (a cell surface antigen present on T lymphocytes) and delays disease progression in patients with stage 2 T1D. The mechanism may involve partial agonistic signalling leading to deactivation of autoreactive CD8+ T lymphocytes and reduced immune-mediated beta-cell destruction. Teplizumab leads to an increase in the proportion of CD8+ T cells with signs of exhaustion in peripheral blood. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| TEIZEILD Concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EE | Ravimiamet | 3139534, 3139545, 3139556 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1105689, 1105690, 1105691 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.